MarketInOut Stock Screener Log In | Sign Up

Spyre Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Spyre Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,023.73 mln
Float82.86 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

122.33
Strong upside

Relative Strength

97 / 100
Top performer

Pre-Tax Margin

-198%
Severely loss-making

ROE

-26.33
Deeply negative

ROA

-23.80
Deeply negative

Business Description

Spyre Therapeutics is a clinical-stage biotech company based in Waltham, Massachusetts, focused on creating new treatments for inflammatory bowel disease and rheumatic conditions. The company is advancing several drug candidates that target specific proteins involved in inflammation, including standalone antibodies and combination therapies designed to address conditions such as ulcerative colitis and Crohn's disease. Formerly known as Aeglea BioTherapeutics, the company adopted its current name in November 2023 and has been operating since its founding in 2013.

Key Fundamentals

EPS-1.92
ROE-26.33
RPS1.07
ROIC-656
ROA-23.80
EBITDA, mln-179
EV / EBITDA-43.85
EV / EBIT-43.85
Revenue, mln90.49

Quote Details

Last 96.56
Change -2.4 (-2.43%)
Open 96.78
Volume 658,464
Turnover 63,581,284
Average Volume 1,308,383

Financial Ratios

Pre-Tax Profit Margin-198
Leverage Ratio1.07
Current Ratio18.53
Price / Book9.14
Price / Tangible Book9.14
Price / Sales98.48

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price122.33
Short Ratio7.98
Short % of Float14.25

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.9% 91 / 100   
1 Month 7.37% 88 / 100   
2 Months -3.48% 44 / 100   
6 Months 39.1% 94 / 100   
1 Year 305% 99 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog